

# **APEC Roundtable Dialogue on Global Regulatory Convergence for Medical Devices & Accelerating Digital Health Regulatory Convergence in the Asia-Pacific**

November 08 - 10 2022 | Seoul, Korea (Hybrid format)

## APEC Roundtable Dialogue

### Workshop on Global Regulatory Convergence for Medical Devices

**Day One: November 8, 2022 (COEX 402 / Webex)**

<i>Advancing Global Regulatory Convergence for Medical Devices and IVDs</i>	
10:30 – 10:45 AM	<p><b>Coffee/Tea Break Following Conclusion of Soonchunhyang University APEC Center of Excellence Workshop</b></p> <p><b>In person participants:</b> Registration and coffee/tea  <b>Virtual participants:</b> Join virtual meeting using <i>[Link will be provided to all registered participants]</i></p>
10:45 – 10:55 AM (10 minutes)	<p><b><u>Host: AHC Representative</u></b></p> <p><b><u>Welcome Remarks:</u></b> Roundtable objectives and event structure (5 minutes each)</p> <ul style="list-style-type: none"> <li><b>Representative,</b> Title, AHC</li> </ul>
<i>Session I: Review of Outcomes and Recommendations from November 2021 Dialogue on Regulatory Flexibilities During COVID-19</i>	
10:55 – 11:30 AM (35 minutes)	<p><b><u>Presentation:</u></b> (25 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li><b>Janet Trunzo,</b> Senior Executive Vice President, Technology and Regulatory Affairs, AdvaMed</li> </ul> <p>Identified key regulatory flexibilities during COVID-19 included:</p> <ul style="list-style-type: none"> <li>Expedited and prioritized review of qualifying products, such as through emergency use pathways;</li> <li>Adding reliance pathways;</li> <li>Having flexible clinical trial requirements; and</li> <li>Adopting digital tools, including permitting electronic submissions and remote inspections.</li> </ul> <p>Opportunities included:</p> <ul style="list-style-type: none"> <li>advancing regulatory reliance and convergence;</li> <li>adopting agile premarket pathways;</li> <li>adopting policies that enable alternative sources of evidence;</li> <li>developing a common emergency use pathway;</li> <li>adopting state-of-the-art digital technologies; and</li> <li>facilitating public-private partnerships.</li> </ul>

**Session II: Review of International Foundational Best Practices and Guidance Documents that Enable the Recommendations of the November 2021 Dialogue**

**WHO Guidance Documents and Global Model Regulatory Framework**

<p>11:30 AM – 12:00 PM (30 minutes)</p>	<p><b><u>Presentations:</u></b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>• <b>Agnes Kijo</b>, Technical officer, Regulation and Safety Unit, World Health Organization</li> </ul> <p>This presentation will overview:</p> <ul style="list-style-type: none"> <li>• Global Model Regulatory Framework</li> <li>• Good reliance practices in the regulation of medical products – Annex 10, <a href="#">WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-Fifth Report</a></li> <li>• Good regulatory practices in the regulation of medical products – Annex 11, <a href="#">WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-Fifth Report</a></li> </ul>
---	---

**IMDRF Guidance Documents**

<p>12:00 – 12:30 PM (30 minutes)</p>	<p><b><u>Presentations:</u></b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>• <b>Melissa Torres</b>, Associate Director for International Affairs, Center for Devices and Radiological Health, U.S. FDA</li> </ul> <p>Topics the presentation will cover include:</p> <ul style="list-style-type: none"> <li>• <a href="#">Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices</a></li> <li>• <a href="#">Principles of Labelling for Medical Devices and IVD Medical Devices</a></li> <li>• <a href="#">Principles Conformity Assessment for IVD Medical Devices</a></li> <li>• <a href="#">Medical Device Single Audit Program (MDSAP)</a></li> </ul>
<p>12:30 – 1:15 PM (45 minutes)</p>	<p><b>Lunch</b></p>

Session III: Panel Discussion on the Implementation of Identified Foundational Best Practices and Guidance Documents to Advance Regulatory Convergence	
1:15 – 2:20 PM (55 minutes)	<p>The panel will review the key takeaways and recommendations from Session II.</p> <p><b>Panelists:</b></p> <p><b>Regulatory Perspective:</b></p> <ul style="list-style-type: none"> <li>• <b>Agnes Kijo</b>, Technical officer, Regulation and Safety Unit, World Health Organization</li> </ul> <p><b>Industry Perspectives:</b></p> <ul style="list-style-type: none"> <li>• <b>Tammy Steuerwald</b>, Global Head of Regulatory Policy, Foundational Principles &amp; Supranational Organizations</li> </ul> <p>15 min Opening Statements (5 min each) 25 min Facilitated discussion around prepared questions 15 min Q&amp;A</p> <ul style="list-style-type: none"> <li>• <b>Moderator: Sandra Ligia González</b>, Executive Secretary, Inter-American Coalition for Regulatory Convergence in the Medical Technology Sector</li> </ul>
2:20 – 2:35 PM (15 minutes)	Coffee / tea break
In-Person Regulatory & Industry Dialogue Sessions	
2:35 – 3:20 PM (45 minutes)	<p><b>Case Study 1: Singapore/Thailand Reliance Pilot</b></p> <ul style="list-style-type: none"> <li>• <i>During COVID-19, Singapore and Thailand undertook an abridged review of their reliance pilot and how it resulted in new regulation</i></li> <li>• <i>Review of how the pilot and subsequent regulations impacted patient access</i></li> </ul> <p>Q&amp;A</p> <p><b>Presenter 1: Miang Tanakasemsub</b>, Head of Regulatory Affairs, J&amp;J  <b>Presenter 2: Patcharaporn Nontasawadsri</b>, Pharmacist, practitioner level, Pre-Marketing Sub-Division, Medical Devices Control Division, FDA, Thailand  <b>Presenter 3: Dr. Lakshmidevi Balakrishnan</b>, Regulatory Consultant, Medical Devices Branch, Singapore Health Sciences Authority</p>

<p>3:20 – 3:50 PM (30 minutes)</p>	<p><b>Case Study 2: Canada &amp; U.S. and the Use of Digital Tools for Premarket Electronic Submissions and Remote Inspections</b></p> <ul style="list-style-type: none"> <li><i>The use of remote inspections proved invaluable in the fight and recovery from COVID-19. Looking forward, the U.S. FDA speaks to the use of remote inspections beyond the pandemic.</i></li> <li><i>Health Canada speaks to the use of electronic submissions in facilitating premarket review and its role in universal dossiers.</i></li> </ul> <p>Q&amp;A</p> <p><b>Presenter : Jesus Rueda</b>, Strategies, Special Projects &amp; International Affairs, MedTech Europe</p>
<p>3:50 – 4:20 PM (30 minutes)</p>	<p><b>Case Study 3: Republic of Korea and the Benefits of Emergency Use Authorizations (EUA)</b></p> <ul style="list-style-type: none"> <li><i>The Republic of Korea overviews its use of EUAs during the pandemic and the benefits of regulatory flexibilities</i></li> </ul> <p>Q&amp;A</p> <p><b>Presenter: Dr. Ho-Sang Jeong</b>, Director, In Vitro Diagnostic Devices Division, NIFDS MFDS</p>
<p>4:20 – 4:30 PM (10 minutes)</p>	<p><b>Day One In-Person Program Closing</b></p>

**Day Two: November 9, 2022 (COEX 402 / Webex)**

<b>Review of Best Practices and Opportunities for Regulatory Innovation</b>	
8:45 – 9:00 AM	<p><b>In person participants:</b> Registration and coffee/tea</p> <p><b>Virtual participants:</b> Join virtual meeting using <a href="#">[Link will be provided to all registered participants]</a></p>
<b>Session I: Deep Dive into the Medical Device Single Audit Program</b>	
9:00 – 9:40 AM (40 min)	<p><b>Presentation:</b> (30minutes / 10minutes Q&amp;A) on the <b>Medical Device Single Audit Program (MDSAP)</b></p> <p><b>Regulatory Perspective:</b></p> <ul style="list-style-type: none"> <li><b>Kenneth Chen</b>, Senior Regulatory Officer, U.S. FDA</li> </ul>
<b>Session II: Opportunities for Innovation</b>	
9:40 – 10:30 AM (50 minutes)	<p><b>Expanding Patient Access Based on Lessons Learned</b></p> <p><i>During the November 2021 roundtable, participants identified key regulatory flexibilities and opportunities to implement lessons learned from COVID-19. This session will feature a presentation on the importance of global regulatory convergence and reliance in expand patient access to vital medical technologies. Thereafter, a panel discussion will seek to synthesize the workshop's recommendations and identify additional opportunities for global regulatory convergence and reliance.</i></p> <p><b>Moderator:</b> <b>Sandra Ligia González</b>, Executive Secretary, Inter-American Coalition for Regulatory Convergence in the Medical Technology Sector</p> <p><b>Panelists:</b></p> <ul style="list-style-type: none"> <li><b>Agnes Kijo</b>, Technical officer, Regulation and Safety Unit, World Health Organization</li> <li><b>Eric Woo</b>, Regional Director, Asia Pacific, ECRI Institute</li> <li><b>Jesus Rueda</b>, Strategies, Special Projects &amp; International Affairs, MedTech Europe</li> <li><b>Janet Trunzo</b>, Senior Executive Vice President, Technology and Regulatory Affairs, AdvaMed</li> <li><b>You Kyoung Lee</b>, Professor, Soonchunhyang University &amp; Director, SCH APEC CoE Team</li> </ul>
	<p>Q&amp;A (10 minutes)</p>
10:30 – 10:40 AM (10 minutes)	<ul style="list-style-type: none"> <li><b>Day Two In-Person Program Closing</b></li> </ul>

## APEC Roundtable Dialogue on Accelerating Digital Health Regulatory Convergence in the Asia-Pacific: Overview of Key IMDRF Documents & Opportunities for Post-Pandemic Regulatory Innovation & Convergence

**Day Two: November 9, 2022 (COEX 402 / Webex)**

Opening & Introduction	
1:30 – 1:45 PM (15 minutes)	<p><b>Host: AHC Representative</b></p> <p><b>Welcome Remarks: Roundtable objectives and event structure</b> (7.5 minutes each)</p> <ul style="list-style-type: none"> <li>Representative, Title, AHC</li> <li>Maggie Henkin, CMI</li> </ul>
SaMD Qualification	
1:45 – 2:15 PM (30 minutes)	<p><b>Presentations: Landscape</b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>Sharad Shukla, Director, Regulatory Affairs, MedTech, Johnson &amp; Johnson</li> <li>Moderator: Maggie Henkin, CMI</li> </ul>
2:15 – 2:45 PM (30 minutes)	<p><b>Presentations: SaMD Risk Classification</b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>Dr. Sethuraman Rama, Director, Medical Devices Branch, Health Sciences Authority (HSA) <ul style="list-style-type: none"> <li>HSA's Guidance "Guidelines on Risk Classification of Standalone Medical Mobile Applications and Qualification of Clinical Decision Support Software (CDSS)", published in April 2022</li> </ul> </li> <li>Moderator: Maggie Henkin, CMI</li> </ul>
Regulatory & Industry Dialogue Sessions	
2:45 – 3:45 PM (60 minutes)	<p><b>Dialogue Session 1: Regulation of Software as Medical Devices – Software Qualification</b> (40 minutes / 20 minutes Q&amp;A)</p> <p><b>Topic : Considerations for Determining if a product is regulated as a device</b></p> <p><b>Panel</b></p> <ul style="list-style-type: none"> <li>Dr. Sethuraman Rama, Director, Medical Devices Branch, HSA, Singapore</li> <li>Dr. David Hau, Senior Medical Adviser, Medical Devices Authorisation Branch at Therapeutic Goods Administration, Australia (IMDRF SaMD Working Group)</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Kitty Mao</b>, Director of Regulatory Affairs, Asia Pacific, GE Healthcare</li> <li>• <u>Moderator</u> : <b>MinYong Choi</b>, Consultant</li> </ul>
3:45 – 4:00 PM (15 minutes)	<b>Coffee / Tea Break</b>
4:00 – 5:00 PM (60 minutes)	<p><b><u>Dialogue Session 2: SaMD Risk Classification</u></b> (40 minutes / 20 minutes Q&amp;A)</p> <p><b><u>Topic: The benefits of the IMDRF risk classification document. Addressing the challenges of applying the IMDRF concepts</u></b></p> <p><b>Panel</b></p> <ul style="list-style-type: none"> <li>• <b>Dr. Sethuraman Rama</b>, Director, Medical Devices Branch, HSA, Singapore</li> <li>• <b>Dr. David Hau</b>, Senior Medical Adviser, Medical Devices Authorisation Branch at Therapeutic Goods Administration, Australia (IMDRF SaMD Working Group)</li> <li>• <b>Sharad Shukla</b>, Director, Regulatory Affairs, MedTech, Johnson &amp; Johnson</li> <li>• <u>Moderator</u> : <b>Dr. MinYoung Kim</b>, Professor, Department of Rehabilitation Medicine, CHA Medical Center</li> </ul>

**Day Three: November 10, 2022 (COEX 301 / Webex)**

<b>Opening &amp; Introduction</b>	
8:45 – 9:00 AM (15 minutes)	<p><b>In person participants:</b> Registration and coffee/tea</p> <p><b>Virtual participants:</b> Join virtual meeting using <b>[Link will be provided to all registered participants]</b></p>
<b>Software Products with Multiple Functions</b>	
9:00 – 9:30 AM (30 minutes)	<p><b><u>Presentations: Software Products with Multiple Functions</u></b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>• <b>Brendan O’Leary</b>, Acting Director, Digital Health Center of Excellence, FDA, USA <ul style="list-style-type: none"> <li>○ U.S. Food and Drug Administration (FDA) – Multiple Function Device Products: Policy and Considerations Guidance for Industry and Food and Drug Administration Staff</li> </ul> </li> <li>• <b>Thierry Sirdey</b>, Head, Department for Medical Devices and Cosmetics and In Vitro Diagnostic Devices, National Agency for the Safety of Medicines and Health Products, France (<b>remote</b>) <ul style="list-style-type: none"> <li>○ <u>Moderator</u>: <b>Maggie Henkin</b>, CMI (<b>in-person</b>)</li> </ul> </li> </ul>



<b>Total Product Life Cycle Management</b>	
9:30 – 10:00 AM (30 minutes)	<p><b><u>Presentations: Considerations for SaMD and SiMD – Alignment of approaches</u></b> (20 minutes / 10 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>• <b>Allan Chuan Qin</b>, Senior Regulatory Affairs Manager for Software Products, China, GE Healthcare: Alignment of SaMD and SiMD</li> </ul>
10:00 – 10:15 AM (15 minutes)	<b>Coffee / Tea Break</b>
10:15 – 11:15 AM (60 minutes)	<p><b><u>Presentations: Change Management</u></b> (20 minutes / 40 minutes Q&amp;A)</p> <ul style="list-style-type: none"> <li>• <b>Brendan O’Leary</b>, Acting Director, Digital Health Center of Excellence, FDA, USA <ul style="list-style-type: none"> <li>○ US FDA – AI/ML-Based SaMD Action Plan</li> <li>○ US FDA's Discussion Paper – Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)</li> </ul> </li> <li>• <b>Cassie Scherer</b>, Senior Director of Digital Health Policy and Regulatory Strategy, Global Regulatory Policy, Medtronic</li> <li>• <b>Moderator: Dr. Jaesoon Choi</b>, Associate professor, Biomedical Engineering, University of Ulsan College of Medicine</li> </ul>
<b>Unique Considerations for AI</b>	
11:15 – 12:00 PM (45 minutes)	<p><b><u>Presentation: Overview of IMDRF AI Technical Documents and Unique Considerations for AI</u></b> (20 minutes)</p> <ul style="list-style-type: none"> <li>• <b>Youngwoo Bae</b>, Assistant Director, Digital Health Devices Division, Department of Medical Device Evaluation, MFDS</li> <li>• <b>Dr. Camille Vidal</b>, Senior Director of Regulatory Affairs for Software, Digital and Advanced Visualization Products, GE Healthcare</li> <li>• <b>Moderator: Maggie Henkin</b>, CMI</li> </ul>
12:00 – 12:15 PM (15 minutes)	<p><b>Day Two Hybrid Program Wrap up &amp; Closing Remarks</b></p> <ul style="list-style-type: none"> <li>• <b>AHC</b></li> <li>• <b>Maggie Henkin</b>, CMI</li> </ul>